PONTE VEDRA, Fla., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in ...

Treace Medical Concepts (TMCI) is jumping 7.5% after investment bank BTIG upgraded the shares to Buy from Neutral. Why BTIG Upgraded the Shares Treace provides technology that facilitates ...

Quite a few insiders have dramatically grown their holdings in Treace Medical Concepts, Inc. (NASDAQ:TMCI) over the past 12 months. An insider's optimism about the company's prospects is a ...

2025 Outlook Treace plans to provide 2025 financial guidance during its fourth quarter 2024 earnings conference call, which is currently scheduled for Thursday, February 27, 2025, at 4:30 p.m ...

Quite a few insiders have dramatically grown their holdings in Treace Medical Concepts, Inc. (NASDAQ:TMCI) over the past 12 months. An insider's optimism about the company's prospects is a positive ...

BTIG analyst Ryan Zimmerman upgraded Treace Medical (TMCI) to Buy from Neutral with a $16 price target The company has pivoted away from offering solely Lapiplasty, its leading technology ...

Treace Medical Concepts (TMCI) is jumping 7.5% after investment bank BTIG upgraded the shares to Buy from Neutral. Why BTIG Upgraded the Shares Treace provides technology that facilitates Lapiplasty ...

(RTTNews) - Treace Medical Concepts, Inc. (TMCI), a leading innovator in medical technologies for bunion and midfoot deformity treatment, announced on Tuesday the successful completion of its ...

Treace Medical Concepts, Inc. has a 1-year low of $3.92 and a 1-year high of $15.98. The company has a current ratio of 4.12, a quick ratio of 2.98 and a debt-to-equity ratio of 0.51.